Expression Patterns of Immune Checkpoints in Breast Cancer Patients
DOI:
https://doi.org/10.54097/ajst.v7i1.10978Keywords:
PD-L1, PD-1, STAT1, Immune checkpoint, Breast cancer.Abstract
Background: immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival (OS). Positive response to PD-1/PD-L1 blockades was observed in the treatment of solid tumors. Breast cancer (BC) patients are no exception. However, the efficacy of immunocheckpoint therapy in BC patients remains poor. A particularly important factor is the lack of studies on the expression patterns of immune checkpoints in BC patients. Methods：This article summarizes the expression of immune checkpoints such as PD-1, PD-L1, STAT1, CTLA-4 in BC, and analyzes the relationship between the expression of these immune checkpoints and OS.Results: It was found that increased expression of PD-1, PD-L1, STAT1, CTLA-4 was associated with poor OS in BC patients. In addition, co-expression of PD-L1 with PD-1, STAT1or CTLA-4 and co-expression of PD-1 with CTLA-4was related to poor OS. We analyzed associations between the proportionate expression of PD-L1 and PD-1, PD-L1 and STAT1, PD-1 and CTLA-4, PD-1 and LAG3, PD-L1 and CTLA-4 in BC patients, there was significance in correlation in both of the BC patients. Conclusions: our results suggest that transcriptome-based co-expression of STAT1 and PD-L1 is a predictor for poor OS in BC patients, which might provide novel insight into designing combinational targeted therapy for BC.
Downloads
References
Topalian SL, Drake CG, Pardoll DM. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell. 2015; 27:450-461.
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:12293-12297.
Muller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, et al. Trastuzumab emtansine (T-DM1) renders HER2(+) breast cancer highly susceptible to CTLA-4/PD-1 blockade. Science Translational Medicine. 2015; 7.
Parra K, Valenzuela P, Lerma N, Gallegos A, Reza LC, Rodriguez G, et al. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. British Journal of Cancer. 2017; 116:324-334.
Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Research and Treatment. 2013; 139:667-676.
Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, et al. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine. 2012; 366:2455-2465.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New England Journal of Medicine. 2012; 366:2443-2454.
Bian L, Zhang HQ, Wang T, Zhang SH, Song HF, Xu ML, et al. JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial. Annals of Translational Medicine. 2019; 7.
Jiang C, Cao SR, Li N, Jiang L, Sun T. PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer. Cancer Cell International. 2019; 19.
Zielinski C, Knapp S, Mascaux C, Hirsch F. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Annals of Oncology. 2013; 24:1170-1179.
Hartkopf AD, Taran FA, Wallwiener M, Walter CB, Kramer B, Grischke EM, et al. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care. 2016; 11:385-390.
Gao MZ, Wang T, Ji LT, Bai SP, Tian LN, Song HJ. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer. Frontiers in Immunology. 2020; 11.
Zhao T, Li Y, Zhang J, Zhang B. PD-L1 expression increased by IFN-gamma via JAK2-STAT1 signaling and predicts a poor survival in colorectal cancer. Oncol Lett. 2020; 20:1127-1134.
Nakayama Y, Mimura K, Tamaki T, Shiraishi K, Kua LF, Koh V, et al. Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer. International Journal of Oncology. 2019; 54:2030-2038.
Owen KL, Brockwell NK, Parker BS. JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. Cancers. 2019; 11.
Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
Sasidharan Nair V, Toor S M, Ali B R, et al. Dual inhibition of stat1 and stat3 activation downregulates expression of pd-l1 in human breast cancer cells[J]. Expert Opin Ther Targets, 2018, 22(6): 547-557.
Wong G L, Manore S G, Doheny D L, et al. Stat family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges[J]. Semin Cancer Biol, 2022, 86(Pt 3): 84-106.
Nakayama Y, Mimura K, Tamaki T, et al. Phospho‑stat1 expression as a potential biomarker for anti‑pd‑1/anti‑pd‑l1 immunotherapy for breast cancer[J]. Int J Oncol, 2019, 54(6): 2030-2038.
Alkhayyal N, Elemam N M, Hussein A, et al. Expression of immune checkpoints (pd-l1 and ido) and tumour-infiltrating lymphocytes in breast cancer[J]. Heliyon, 2022, 8(9): e10482.
Dill E A, Dillon P M, Bullock T N, et al. Ido expression in breast cancer: An assessment of 281 primary and metastatic cases with comparison to pd-l1[J]. Mod Pathol, 2018, 31(10): 1513-1522.
Kern R, Panis C. Ctla-4 expression and its clinical significance in breast cancer[J]. Arch Immunol Ther Exp (Warsz), 2021, 69(1): 16.
Fang J, Chen F, Liu D, et al. Prognostic value of immune checkpoint molecules in breast cancer[J]. Biosci Rep, 2020, 40(7).
Du H, Yi Z, Wang L, et al. The co-expression characteristics of lag3 and pd-1 on the t cells of patients with breast cancer reveal a new therapeutic strategy[J]. Int Immunopharmacol, 2020, 78: 106113.
Pedraza V, Gomez-Capilla JA, Escaramis G, Gomez C, Torne P, Rivera JM, et al. Gene Expression Signatures in Breast Cancer Distinguish Phenotype Characteristics, Histologic Subtypes, and Tumor Invasiveness. Cancer. 2010; 116:486-496.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods. 2001; 25:402-408.
Li G, Zhang Z, Chen Z, Liu B, Wu H. LncRNA DLEU2 is activated by STAT1 and induces gastric cancer development via targeting miR-23b-3p/NOTCH2 axis and Notch signaling pathway. Life Sci. 2021; 277:119419.
Li X, Wang Z, Zhang SJ, Yao QH, Chen W, Liu FY. Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis. Oncology Letters. 2021; 21.
Li X, Wang FC, Xu XL, Zhang JG, Xu GX. The Dual Role of STAT1 in Ovarian Cancer: Insight Into Molecular Mechanisms and Application Potentials. Frontiers in Cell and Developmental Biology. 2021; 9.
Totten SP, Im YK, Cepeda Canedo E, Najyb O, Nguyen A, Hebert S, et al. STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nat Commun. 2021; 12:3299.
Nair VS, Elkord E. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells (vol 96, pg 21, 2018). Immunology and Cell Biology 2018;96:236-236.
Chaudhary B, Elkord E. Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines. 2016; 4.
Nair VS, El Salhat H, Taha RZ, John A, Ali BR, Elkord E. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clinical Epigenetics. 2018; 10.
Saleh R, Toor SM, Khalaf S, Elkord E. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells. Vaccines. 2019; 7.
Ibuki Y, Takahashi Y, Tamari K, Minami K, Seo Y, Isohashi F, et al. Local hyperthermia combined with CTLA-4 blockade induces both local and abscopal effects in a murine breast cancer model. International Journal of Hyperthermia. 2021; 38:363-371.
Du HM, Yi ZY, Wang L, Li Z, Niu BL, Ren GS. The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy. International Immunopharmacology. 2020; 78.
Ye Q, Wang CL, Xian J, Zhang M, Cao YJ, Cao YD. Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer. Human Pathology. 2018; 75:81-90.
Sivapiragasam A, Ashok Kumar P, Sokol ES, Albacker LA, Killian JK, Ramkissoon SH, et al. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. Cancer Med. 2021; 10:53-61.
Bottai G, Raschioni C, Losurdo A, Di Tommaso L, Tinterri C, Torrisi R, et al. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Res. 2016; 18:121.
Downloads
Published
Issue
Section
How to Cite
